Elderly breast cancer patients treated with Nab-paclitaxel: Results in real clinical practice

Gascón Ruiz, M. ; Casas Deza, D. ; Lafuente Blasco, M. (Universidad de Zaragoza) ; Sesma Goñi, A. ; Cruellas Lapeña, M. ; Alonso Martín, N. ; Zapata García, M. ; Ocáriz Diez, M. ; Zurera Berjaga, M. ; Quilez Bielsa, E. ; Murillo Jaso, L. ; Andrés Conejero, R. (Universidad de Zaragoza)

Resumen: Objective: Clinical trials have shown that Nab-paclitaxel is more effective than paclitaxel in the treatment of metastatic breast cancer (MBC). Although the incidence of cancer increases with age, elderly patients are under-represented in clinical trials and tend to receive suboptimal treatment to avoid toxicity. The main aim of our study was to compare progression-free survival (PFS) among patients older and younger than 65 years treated with Nab-paclitaxel in real-world clinical practice. A secondary aim was to assess overall survival (OS) as well as the response rate and toxicity. Methods and patients: This single-centre study retrospectively analyzed a cohort of 60 patients with MBC treated with Nab-paclitaxel monotherapy in Hospital Clínico Lozano Blesa de Zaragoza. Results: The median PFS was 5.92 months (3.62–11.2) in patients < 65 years and was 5.06 months (4.31–12.4) in those =65 years (p = 0.868). The median OS was 26.9 months (18.6–30.7) in patients < 65 years and was 20.3 months (11.4–33.6) in those =65 years (p = 0.138). Conclusions: Although patients in the cohort studied had a median age of 60.45 years, which is higher than the median age in most clinical trials, PFS and OS in conditions of real-world clinical practice were similar to previously published data. The results of the use of Nab-paclitaxel in patients older than 65 years are similar to those in younger patients, with no additional toxicity problems. The results of our study agree with those of other notable studies.

Idioma: Inglés

DOI: 10.1016/j.senol.2020.06.006

Año: 2021

Publicado en: Revista de Senologia y Patologia Mamaria 34, 2 (2021), 93-99
ISSN: 0214-1582

Factor impacto CITESCORE: 0.3 - Medicine (Q4)

Factor impacto SCIMAGO: 0.118 - Obstetrics and Gynecology (Q4) - Surgery (Q4) - Oncology (Q4)

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Estadís. Investig. Opera. (Dpto. Métodos Estadísticos)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)